Amylyx Pharmaceuticals has decided to withdraw its ALS drug, Relyvrio, from the market. ALS, also known as Lou Gehrig’s disease, is a fatal disease affecting muscle function.
What Happened?
Relyvrio did not prove effective in a large clinical trial and did not perform any better than a placebo for improving either quality of life or survival rates.
Amylyx announced it will continue its ALS research and other potential treatments are being explored.
If you have any medical malpractice questions, contact us today.